155 related articles for article (PubMed ID: 37731263)
1. Secukinumab Therapy in Refractory Juvenile Idiopathic Arthritis.
Nelson MC; Manos CK
J Investig Med High Impact Case Rep; 2023; 11():23247096231200403. PubMed ID: 37731263
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial.
Brunner HI; Foeldvari I; Alexeeva E; Ayaz NA; Calvo Penades I; Kasapcopur O; Chasnyk VG; Hufnagel M; Żuber Z; Schulert G; Ozen S; Rakhimyanova A; Ramanan A; Scott C; Sozeri B; Zholobova E; Martin R; Zhu X; Whelan S; Pricop L; Martini A; Lovell D; Ruperto N;
Ann Rheum Dis; 2023 Jan; 82(1):154-160. PubMed ID: 35961761
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of etanercept in children with the JIA categories extended oligoarthritis, enthesitis-related arthritis and psoriasis arthritis.
Windschall D; Müller T; Becker I; Horneff G
Clin Rheumatol; 2015 Jan; 34(1):61-9. PubMed ID: 25034081
[TBL] [Abstract][Full Text] [Related]
4. Etanercept treatment for extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, or psoriatic arthritis: 6-year efficacy and safety data from an open-label trial.
Foeldvari I; Constantin T; Vojinović J; Horneff G; Chasnyk V; Dehoorne J; Panaviene V; Sušić G; Stanevicha V; Kobusinska K; Zuber Z; Dobrzyniecka B; Nikishina I; Bader-Meunier B; Breda L; Doležalová P; Job-Deslandre C; Rumba-Rozenfelde I; Wulffraat N; Pedersen RD; Bukowski JF; Vlahos B; Martini A; Ruperto N;
Arthritis Res Ther; 2019 May; 21(1):125. PubMed ID: 31122296
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study.
Horneff G; Burgos-Vargas R; Constantin T; Foeldvari I; Vojinovic J; Chasnyk VG; Dehoorne J; Panaviene V; Susic G; Stanevica V; Kobusinska K; Zuber Z; Mouy R; Rumba-Rozenfelde I; Breda L; Dolezalova P; Job-Deslandre C; Wulffraat N; Alvarez D; Zang C; Wajdula J; Woodworth D; Vlahos B; Martini A; Ruperto N;
Ann Rheum Dis; 2014 Jun; 73(6):1114-22. PubMed ID: 23696632
[TBL] [Abstract][Full Text] [Related]
6. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab-Induced Crohn's Disease in a Patient Treated for Juvenile Idiopathic Arthritis.
Edupuganti S; Khine S; Gupta R; Yadav D; Singh A
Cureus; 2023 Aug; 15(8):e43825. PubMed ID: 37736437
[TBL] [Abstract][Full Text] [Related]
8. Enthesitis-related arthritis is the most common category of juvenile idiopathic arthritis in Taiwan and presents persistent active disease.
Shih YJ; Yang YH; Lin CY; Chang CL; Chiang BL
Pediatr Rheumatol Online J; 2019 Aug; 17(1):58. PubMed ID: 31443722
[TBL] [Abstract][Full Text] [Related]
9. Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.
Ho ACH; Wong SN; Leung LCK; Chan WKY; Chong PCY; Tse NKC; Yeung RHM; Kong SY; Lee KP
Hong Kong Med J; 2020 Feb; 26(1):56-65. PubMed ID: 32077861
[TBL] [Abstract][Full Text] [Related]
10. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
11. Importance of pediatric rheumatologists and transitional care for juvenile idiopathic arthritis-associated uveitis: a retrospective series of 9 cases.
Yamazaki S; Shimbo A; Akutsu Y; Takase H; Morio T; Mori M
Pediatr Rheumatol Online J; 2020 Mar; 18(1):26. PubMed ID: 32293465
[TBL] [Abstract][Full Text] [Related]
12. Frequency of juvenile idiopathic arthritis and associated uveitis in pediatric rheumatology clinics in Turkey: A retrospective study, JUPITER.
Sahin S; Acari C; Sonmez HE; Kilic FZ; Sag E; Dundar HA; Adrovic A; Demir S; Barut K; Bilginer Y; Sozeri B; Unsal E; Ozen S; Kasapcopur O
Pediatr Rheumatol Online J; 2021 Aug; 19(1):134. PubMed ID: 34425847
[TBL] [Abstract][Full Text] [Related]
13. Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
Beukelman T; Ringold S; Davis TE; DeWitt EM; Pelajo CF; Weiss PF; Kimura Y;
J Rheumatol; 2012 Sep; 39(9):1867-74. PubMed ID: 22859354
[TBL] [Abstract][Full Text] [Related]
14. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry.
Weiss PF; Beukelman T; Schanberg LE; Kimura Y; Colbert RA;
J Rheumatol; 2012 Dec; 39(12):2341-51. PubMed ID: 23070991
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab in combination with methotrexate for refractory uveitis associated with juvenile idiopathic arthritis: a RCT.
Ramanan AV; Dick AD; Jones AP; Hughes DA; McKay A; Rosala-Hallas A; Williamson PR; Hardwick B; Hickey H; Rainford N; Hickey G; Kolamunnage-Dona R; Culeddu G; Plumpton C; Wood E; Compeyrot-Lacassagne S; Woo P; Edelsten C; Beresford MW
Health Technol Assess; 2019 Apr; 23(15):1-140. PubMed ID: 31033434
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab for children and adolescents with enthesitis-related arthritis and psoriatic arthritis:
Bagri NK; King H; Ramanan AV
Expert Rev Clin Immunol; 2024 May; 20(5):435-440. PubMed ID: 38186357
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of etanercept in patients with the enthesitis-related arthritis category of juvenile idiopathic arthritis: results from a phase III randomized, double-blind study.
Horneff G; Foeldvari I; Minden K; Trauzeddel R; Kümmerle-Deschner JB; Tenbrock K; Ganser G; Huppertz HI
Arthritis Rheumatol; 2015 May; 67(8):2240-9. PubMed ID: 25891010
[TBL] [Abstract][Full Text] [Related]
19. Management of Children with Juvenile Idiopathic Arthritis.
Viswanathan V; Murray KJ
Indian J Pediatr; 2016 Jan; 83(1):63-70. PubMed ID: 26639461
[TBL] [Abstract][Full Text] [Related]
20. Evidence for Tocilizumab as a Treatment Option in Refractory Uveitis Associated with Juvenile Idiopathic Arthritis.
Tappeiner C; Mesquida M; Adán A; Anton J; Ramanan AV; Carreno E; Mackensen F; Kotaniemi K; de Boer JH; Bou R; de Vicuña CG; Heiligenhaus A
J Rheumatol; 2016 Dec; 43(12):2183-2188. PubMed ID: 27633821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
